Praxis Precision Medicines Past Earnings Performance
Past criteria checks 0/6
Praxis Precision Medicines's earnings have been declining at an average annual rate of -18.5%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 81.8% per year.
Key information
-18.5%
Earnings growth rate
64.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 81.8% |
| Return on equity | -39.5% |
| Net Margin | -9,409.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Praxis Precision Medicines: Great Price Movement, But Still Not Convinced
Oct 13We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
Aug 30
Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
May 14Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
Mar 26Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?
Feb 27Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Nov 29Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Aug 14Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Feb 10Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Oct 21Praxis Precision Medicines GAAP EPS of -$1.32 misses by $0.02
Aug 08Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline
Jun 10We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
May 15Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Jan 27Praxis Precision Medicines: Genetic Medicines For Neurological Disease
Nov 23We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
Oct 14Praxis' PRAX-562 wins Orphan Drug designation for rare encephalopathy
Apr 30Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Mar 12Read This Before Selling Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares
Jan 18Praxis Precision's pediatric epilepsy therapies nab Rare Pediatric and Orphan Drug tags in U.S.
Jan 07Praxis Precision Medicine plummets 27% on clinical hold on lead drug
Nov 10Revenue & Expenses Breakdown
How Praxis Precision Medicines makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2 | -151 | 51 | 0 |
| 30 Jun 24 | 2 | -124 | 45 | 0 |
| 31 Mar 24 | 2 | -125 | 44 | 0 |
| 31 Dec 23 | 2 | -123 | 42 | 0 |
| 30 Sep 23 | 2 | -138 | 45 | 0 |
| 30 Jun 23 | 1 | -157 | 50 | -89 |
| 31 Mar 23 | 1 | -183 | 57 | 0 |
| 31 Dec 22 | 0 | -214 | 60 | 0 |
| 30 Sep 22 | 0 | -231 | 62 | 44 |
| 30 Jun 22 | 0 | -232 | 59 | 166 |
| 31 Mar 22 | 0 | -208 | 54 | 102 |
| 31 Dec 21 | 0 | -167 | 47 | 120 |
| 30 Sep 21 | 0 | -135 | 41 | 93 |
| 30 Jun 21 | 0 | -111 | 33 | 73 |
| 31 Mar 21 | 0 | -88 | 25 | 56 |
| 31 Dec 20 | 0 | -70 | 17 | 45 |
| 30 Sep 20 | 0 | -53 | 9 | 34 |
| 30 Jun 20 | 0 | -44 | 7 | 31 |
| 31 Mar 20 | 0 | -41 | 6 | 29 |
| 31 Dec 19 | 0 | -41 | 6 | 30 |
Quality Earnings: PRAX is currently unprofitable.
Growing Profit Margin: PRAX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRAX is unprofitable, and losses have increased over the past 5 years at a rate of 18.5% per year.
Accelerating Growth: Unable to compare PRAX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: PRAX has a negative Return on Equity (-39.46%), as it is currently unprofitable.